SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following a preliminary update that revealed record-breaking demand and a massive jump in gross margins, significantly easing investor concerns over profitability. The community is buzzing with anticipation for a potential short squeeze, as bullish traders point to the substantial order backlog and improving fundamentals as catalysts to challenge short positions.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is currently trending due to its pivot toward an AI-native infrastructure and the launch of privacy-focused 'Confidential Intents,' which has sparked community debate over its long-term potential compared to other layer-1 protocols. Despite market-wide volatility, investors are actively discussing whether these utility-driven updates position it for a recovery as capital rotates back into AI-centric blockchain projects.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors closely monitor its upcoming earnings release for guidance on AI infrastructure spending, which remains the pivotal catalyst for the broader sector. The community is actively debating the company's long-term AI strategy, potential capital expenditure plans, and the impact of its cloud growth versus intense competition in the AI model space.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing high volatility as the community remains deeply divided between long-term holders betting on IoT utility and skeptics calling for further price declines. The discourse is fueled by intense debate over institutional accumulation, the impact of recent ecosystem expansion, and the asset's performance relative to broader market trends.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh significant contract wins and strong production delivery figures against lingering trade tensions with Airbus and concerns over the company's financial debt load. The community remains deeply divided, with bulls pointing to the record backlog as a generational buying opportunity while bears focus on persistent execution risks and the stock's recent underperformance.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors debate its positioning within the AI and advertising landscape, while community members actively discuss technical price action, potential earnings catalysts, and comparisons to peers like Meta. Sentiment remains split between those focused on long-term growth and those expressing frustration over short-term volatility and institutional trading patterns.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending following the abrupt departure of its CEO and the announcement of a new executive order aimed at accelerating FDA review pathways for psychedelic treatments. The community is actively discussing the company's clinical milestone of advancing enrollment in its Phase 3 MDD study alongside ongoing speculation regarding potential consolidation and the company's financial outlook.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on its pivot into AI infrastructure through the Northern Data acquisition and strong strategic backing from Tether. The community is actively discussing the stock's significant short interest and the potential for a liquidity-driven squeeze as they anticipate future cloud compute contracts and updated financial guidance.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to a new executive order aimed at strengthening U.S. defense supply chains and reducing dependence on foreign critical minerals. The community is actively discussing the stock's long-term strategic value in national security, while short-term sentiment remains divided between those viewing the current price as a buying opportunity and others concerned about significant short interest and volatile price action.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is attracting significant attention as investors react to the company's deepening integration of AI and autonomous lab automation, underscored by a high-profile demonstration with OpenAI that successfully lowered protein synthesis costs. Community discussion remains heavily polarized between bulls betting on the stock as a critical infrastructure play for the future of synthetic biology, and bears who cite ongoing cash burn, poor past performance, and the potential for future share dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’

Equity

Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish

Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...

CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data  

The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo. 

CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches

Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow 

Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High  - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...

Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...

Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CADLCandel Therapeutics Inc

Fundamentals

Latest CADL News